Results 191 to 200 of about 41,944 (264)

PARP inhibitors target cellular energy metabolism: Mechanisms of action and clinical implications. [PDF]

Transl Oncol
Li J, Mu D, Li J, Lan M, Wu W, Zhang S, Dai Y.   +6 more
europepmc   +1 more source

Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching. [PDF]

Protein Cell
Liu C, Xu F, Wu Y, Li J, Ni M, Xia S, Chen L, Zhao H, Yu M, Zhou Y, Zhang M, Li J, Wu X, Huang Y, Zhu T, Chen X.   +15 more
europepmc   +1 more source

Augmented myeloablative conditioning with olaparib in allogeneic hematopoietic stem cell transplantation for relapsed/refractory RUNX1::RUNX1T1-positive acute myeloid leukemia. [PDF]

Front Oncol
Xue S, Ma W, Chen M, Sun HP, Cao XY.
europepmc   +1 more source

Enhanced Antitumor Response in Breast Cancer via Parthanatos Activation Mediated by the Synergistic Effect of Etoposide and Resveratrol. [PDF]

Curr Issues Mol Biol
Taghavi Pourianazar N, Abdullah N.
europepmc   +1 more source

Correction: Cosegregation analysis following an excellent response to olaparib in a pancreatic cancer patient carrier of BRCA2:c.7892 T > C variant enables its reclassification from VUS to pathogenic. [PDF]

BJC Rep
Strojnik K, Blatnik A, Krajc M, Novaković A, Ignjatović M, Ocvirk J, Stegel V, Škerl P, Klančar G, Novaković S, Šetrajčič Dragoš V.   +10 more
europepmc   +1 more source

Targeting poly(ADP-ribose) polymerase in metastatic prostate cancer: current landscape and future directions. [PDF]

Curr Opin Oncol
Shi X, Rifai S, Meher Z, Hussain A.
europepmc   +1 more source

Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer. [PDF]

Target Oncol
Nishimyo K, Ishikawa KB, Aoki D, Fushimi K, Yamazaki T.   +4 more
europepmc   +1 more source

Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer. [PDF]

Nat Commun
Nan Y, Wang K, Hu M, Luo Q, Wu X, Yu X, Zhou X, Chen L, Li B, Cui Z, Liu Z.   +10 more
europepmc   +1 more source

Replication protein A protects lagging strand gaps, restricting PARP inhibitor-induced synthetic lethality in BRCA1-deficient tumors. [PDF]

Nucleic Acids Res
VanderVere-Carozza PS, Jordan MR, Garrett JE, Pollok KE, Pawelczak KS, Turchi JJ.   +5 more
europepmc   +1 more source

LINC00467 mediates PARP inhibitor resistance in high-grade serous ovarian cancer by regulating miR-485-5p/RAD50 axis. [PDF]

J Ovarian Res
Li X, Xiang Y, Gao J, Zong H, Li M, Gao R, Zhang H.   +6 more
europepmc   +1 more source